Published on GHDx (https://ghdx.healthdata.org)

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study

General Info

Geography 
South Africa (ZAF)
Time period covered 
January, 2007 - December, 2007
Data type
Scientific literature
Keywords 
Anogenital herpes

Citation

Authors 
Gray GE, Allen M, Moodie Z, Churchyard G, Bekker L-G, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, Roux S, Mathebula M, Naicker N, Ducar C, Carter DK, Puren A, Eaton N, McElrath MJ, Robertson M, Corey L, Kublin JG, HVTN 503/Phambili study team
Journal 
Lancet Infect Dis
Pages 
507–15
Publication year 
2011
Suggested citation 
Gray GE, Allen M, Moodie Z, Churchyard G, Bekker L-G, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, Roux S, Mathebula M, Naicker N, Ducar C, Carter DK, Puren A, Eaton N, McElrath MJ, Robertson M, Corey L, Kublin JG, HVTN 503/Phambili study team. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011; 11(7): 507–15.
Source URL:https://ghdx.healthdata.org/record/safety-and-efficacy-hvtn-503phambili-study-clade-b-based-hiv-1-vaccine-south-africa-double